🚀Enjoy a 7-Day Free Trial Until Jul 20, 2024!

BI

bioAffinity Technologies IncNASDAQ BIAF Stock Report

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is BIAF undervalued compared to its fair value?

The fair value of BIAF stock is hidden USD. Relative to the market price of 2.56 USD bioAffinity Technologies Inc is hidden.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texa...[More about valuation]

bioAffinity Technologies Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.028 $B

Price:

2.56 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.263

FINANCIALS

bioAffinity Technologies financial for reporting period

Income Statement

0.0003 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0023 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0023 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.0003 B 100%
0.0002 B 73%
-0.0023 B -763%
-0.0023 B -763%

Balance Sheet

0.01 B
0.007 B

Financial Position Analysis

Assets

0.01 B
Current Assets
0.006 B
Total non-current assets
0.0042 B

Total current liabilities
0.002 B
Total non-current liabilities
0.0012 B

Cash Flow Statement

-0.0016 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0015 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

bioAffinity Technologies fundamental analysis for trailing twelve months (TTM)

Profitability score


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-81 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-69 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is BIAF attractive for investment based on fundamental analysis?

BIAF stock rating is hidden. bioAffinity Technologies is a hidden by Eyestock methodology.

Get BIAF Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-2 259

Gross Margin:

75

CFO / Debt ratio:

hidden

Current ratio:

7.876

Debt / Equity ratio:

0.049

ROE:

-81

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

BIAF analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for BIAF to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

bioAffinity Technologies Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

bioAffinity Technologies Inc dividends

BIAF dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About BIAF stock

About the company bioAffinity Technologies Inc

Market cap $B

0.028

Dividend yield

Shares outstanding

8.36975 B

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas. The company went IPO on 2022-08-26. The firm is focused on addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as a targeted cancer treatment. The firm develops noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Its lead product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. Through its wholly owned subsidiary, OncoSelect Therapeutics, LLC, the Company’s research is engaged in the discoveries and advancement of cancer therapeutics that specifically and selectively target cancer cells. The company is focused on expanding its platform technologies in developing tests that detect and therapies that target various types of cancer and potentially other diseases.

BIAF profile

  • Ticker

    BIAF

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    26 August 2022

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

  • City

    San Antonio

  • Address

    22211 West Interstate-10, Suite 1206

  • Cusip

    09076W109